title: Ototoxicity following pediatric hematopoietic stem cell transplantation: a prospective cohort study.
abstract: BACKGROUND
  Our objectives were to describe the frequency and determine risk factors for hearing deterioration following pediatric stem cell transplantation (SCT).
  
  
  METHODS
  In this prospective cohort study, we performed pure tone audiometry and measured otoacoustic emissions (OAE) prior to and following SCT. Worse hearing was considered deterioration in either audiometry or OAE.
  
  
  RESULTS
  Between October 2000 and November 2002, 45 informative audiometry or OAE results were obtained. Hearing deteriorated following SCT in 20/45 (44%) of these children. Those with worse hearing following SCT were more likely to have neuroblastoma (odds ratio [OR] 16.0 [95% CI 1.8, 143.2; P = 0.003]), receive carboplatin conditioning (OR 7.7 [95% CI 1.4, 41.9; P = 0.01]), have abnormal baseline hearing (OR 5.1 [95% CI 1.3, 19.5; P = 0.02]), and have higher baseline serum creatinine (OR for every increase of 5 micromol/L of serum creatinine of 1.5 [95% CI 1.03, 2.1; P = 0.03]).
  
  
  CONCLUSIONS
  Many children who undergo SCT will have deterioration in hearing following SCT. A high-risk group of children can be delineated who may benefit from more intensive audiological monitoring following SCT.
authors.affiliation: Department of Pediatrics, University of Toronto, Ontario, Canada.
authors.forename: Angela
authors.initials: A
authors.lastname: Punnett
authors.forename: Bonnie
authors.initials: B
authors.lastname: Bliss
authors.forename: L Lee
authors.initials: LL
authors.lastname: Dupuis
authors.forename: Mohamed
authors.initials: M
authors.lastname: Abdolell
authors.forename: John
authors.initials: J
authors.lastname: Doyle
authors.forename: Lillian
authors.initials: L
authors.lastname: Sung
mesh_terms: D001299:Audiometry; D002648:Child; D015331:Cohort Studies; D003404:Creatinine / Q000097:blood; D005260:Female; D006311:Hearing Disorders / Q000209:etiology*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007938:Leukemia / Q000628:therapy; D008297:Male; D008059:Mucopolysaccharidosis I / Q000628:therapy; D009447:Neuroblastoma / Q000628:therapy; D011446:Prospective Studies; D012307:Risk Factors
chemical_list: D003404:Creatinine